for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF). “This most recent meeting with PMDA had several important outcomes,” said Peter Altman, Ph.D., BioCardia’s President ...
Factors portending the greatest risk for cardiovascular death in control patients were inflammation (baseline plasma high-sensitivity C-reactive protein ≥2 mg/L; p=0.003) and ischemic HFrEF etiology ...